Real-World check: does upadacitinib tame ulcerative colitis in china?

NCT ID NCT06838845

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will collect routine medical data over one year to see if the drug improves symptoms like bloody diarrhea. No extra tests or visits are required beyond standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib
What this could lead to: If successful, this study could confirm that upadacitinib is effective for managing ulcerative colitis in Chinese patients, supporting its use in routine care.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only follows 80 people for one year, which is small and short-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997
RECRUITING

Guangzhou, Guangdong, 510080, China
The Second Affiliated Hospital Of Zhengzhou University /ID# 274754
RECRUITING

Zhengzhou, Henan, 450014, China
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753
RECRUITING

Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.